Browsing: STAT+

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of Zoom meetings, deadlines, and bustling about has predictably returned. Not surprising, though, is it? To cope, we are pursuing the usual ritual of firing up the coffee kettle and brewing cups…

After months of anticipation, the Food and Drug Administration gave tentative approval to Dr. Reddy’s Laboratories to make a generic version of a groundbreaking HIV prevention medicine, a key step in widening access for dozens of low- and middle-income countries.

This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.

No matter what happens on Election Day, the midterms will have sweeping implications for American health care

Kristin Gills knew the drill. She peed in the cup, and the doctor confirmed her suspicion. He prescribed antibiotics. Before she left Methodist Legacy ER & Urgent Care in Allen, Texas, Gills paid her $211 bill and figured that was the end of it. 

Health officials hoping to boost adoption of artificial intelligence in health care have been moving behind the scenes to address brewing conflict between states and the federal government over the technology.

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We will manicure the Pharmalot grounds, catch up on our reading, and mosey about town. We also hope…

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

On Wednesday night in Clive, Iowa, a parade of Make America Healthy Again activists and Republican candidates decried Big Agriculture, stressed the rise in chronic disease in America, and called for the Covid-19 vaccine to be removed from the market. 

The middlemen that oversee prescription drug spending for employers and workers will soon have to tell their clients all the different ways they get paid, a significant move that will unlock reams of highly protected data.